|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-9-9
|
|
pubmed:abstractText |
The objective of improving the quality of responses of chronic lymphocytic leukemia (CLL) patients has led to the design of protocols that combine fludarabine (FDR) with synergistic drugs. We evaluated the efficacy and toxicity of a schedule that includes fludarabine, ara-C, novantrone and dexamethasone (FAND) for the management of previously treated CLL patients under 60 years old.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
926-33
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12217804-Adult,
pubmed-meshheading:12217804-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12217804-Cytarabine,
pubmed-meshheading:12217804-Dexamethasone,
pubmed-meshheading:12217804-Disease Progression,
pubmed-meshheading:12217804-Female,
pubmed-meshheading:12217804-Humans,
pubmed-meshheading:12217804-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:12217804-Male,
pubmed-meshheading:12217804-Middle Aged,
pubmed-meshheading:12217804-Mitoxantrone,
pubmed-meshheading:12217804-Survival Analysis,
pubmed-meshheading:12217804-Time Factors,
pubmed-meshheading:12217804-Vidarabine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
|
|
pubmed:affiliation |
Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, via Benevento 6, 00161 Rome, Italy. mauro@bce.med.uniroma1.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
